Key Highlights

● Modular Medical soared on November 9 after sharing survey data.

● Nearly half of 303 participants in the final phase were interested in the device.

● Shares were up sharply to about $1.85.

● It announced a positive ISO 13485 certification decision on October 27.

A survey that moved the stock

Modular Medical (NASDAQ:MODD) soared on Monday, November 9, 2026, after the company shared survey data showing strong patient interest in its Pivot patch insulin pump. Nearly half of the 303 participants in the survey's final phase expressed interest in the device.

The shares were up sharply to about $1.85. For a stock trading below $2, even modest dollar moves can translate into big swings, and Monday's gain was among the more dramatic on the Nasdaq.

What the Pivot pump is

Modular Medical is developing the Pivot, a patch-style insulin pump for people with diabetes. Patch pumps attach directly to the body and deliver insulin without the long tubing used by traditional pumps, which many users find more convenient and discreet. The company aims to make pump therapy more accessible and affordable for a broader group of patients.

Survey data on patient interest is not the same as clinical or sales data. It does not show how a device performs or how many units a company will sell. But for an early-stage medical device maker, signs of Demand can help investors gauge the potential market and may support conversations with insurers, distributors and partners.

An earlier milestone

Monday's news followed an earlier step for the company. On October 27, Modular Medical announced a positive ISO 13485 certification decision. ISO 13485 is an international quality management standard for medical device manufacturers. Certification is often an important building block for companies seeking to bring devices to market, because it shows that design and Manufacturing processes meet recognized quality requirements.

Taken together, the certification and the survey results suggest Modular Medical is working through the practical steps needed to move Pivot toward commercialization.

A friendly market for small names

Modular Medical's surge came on a day when investors were willing to take on risk. The Nasdaq Composite climbed 673.71 points to 25,253.14, its best session since July 30. The Russell 2000 jumped 86.71 points to 2,840.81, its strongest day since March 31, and the S&P 500 rose 173.08 points to 7,549.94.

Falling oil prices, driven by hopes for a US-Iran peace deal, eased Inflation worries, while a sharp rebound in semiconductor stocks lifted the tech-heavy Nasdaq. On the Nasdaq, advancing stocks outnumbered decliners by more than three to one, according to news reports.

Health care saw plenty of action. Immunovant (NASDAQ:IMVT) and Vir Biotechnology (NASDAQ:VIR) jumped on positive trial data, while Zura Bio (NASDAQ:ZURA) collapsed after a study missed its main goal.

Volatility comes with the territory

Micro-cap stocks like Modular Medical can move dramatically on relatively limited news, in both directions. Lower share prices, smaller market values and thinner trading can amplify reactions. That makes it especially important for investors to distinguish between early indicators, such as survey interest, and later-stage milestones, such as regulatory clearance and commercial sales.

Commercial Rollout Questions

Investors will look for updates on Pivot's regulatory path, manufacturing readiness and any plans for a commercial launch. Details on pricing, insurance coverage and distribution partnerships would help clarify how the company intends to turn patient interest into revenue.

Funding is another key Factor for early-stage device makers. On the macro side, Tuesday's October Consumer Price Index is the last inflation reading before the Federal Reserve's December 8-9 meeting, where a rate hike is widely expected, and interest-rate expectations can affect financing conditions for small companies.